Armin Ghobadi, MD, on Helping Expand CAR T Cells With NT-I7

Video

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed updated data from a study of NT-I7 and tisa-cel presented at ASH 2022.

“NT-I7 enhances the proliferation of the T cells and function of them, not only in the peripheral blood, but also in the tissue. So, the idea here was you give the patient's CART and maybe they don't expand enough,or they go down quickly. We are trying to add this booster with the hope that it helps with the proliferation and expansion of CAR T cells and bystander T cells and hopefully yields better complete response rate and better progression free survival.”

NT-I7 (efineptakin alfa; NeoImmune Tech), a long-acting human IL-7, was well-tolerated in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL) and increased absolute lymphocyte counts (ALC) and chimeric antigen receptor (CAR) T-cell expansion when administered after tisagenlecleucel (tisa-cel; Kymriah). Updated data from a phase 1b study (NCT05075603) of the combination were presented at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana by Armin Ghobadi, MD, associate professor medicine, Siteman Cancer Center, Washington University in St. Louis School of Medicine.

CGTLive spoke to Ghobadi to learn more about NT-I7 and how it could help improve outcomes for patients with r/r LBCL after CAR T infusion. He discussed the favorable safety profile seen so far in the study and the increased ALC and CAR T cell counts.

Click here to read more coverage of the 2022 ASH meeting.

REFERENCE
Ghobadi A, Budde EL, Galal A, et al. A phase 1b dose expansion study evaluating safety, preliminary anti-tumor activity, and accelerated T cell reconstitution with NT-I7 (Efineptakin Alfa), a long-acting human IL-7, administered following tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.